Objectives:

The aim of these Clinical Practice Guidelines is to provide evidence-based recommendations to assist healthcare providers in the screening, diagnosis and management of patients with postmenopausal osteoporosis (OP).

Methods: 

A list of key clinical questions on the assessment, diagnosis and treatment of OP was formulated. A literature search using the PubMed, Medline, Cochrane Databases of Systematic Reviews, and OVID electronic databases identified all relevant articles on OP based on the key clinical questions, from 2014 onwards, to update from the 2015 edition. The articles were graded using the SIGN50 format. For each statement, studies with the highest level of evidence were used to frame the recommendation.

Results: 

This article summarizes the diagnostic and treatment pathways for postmenopausal OP. Risk stratification of patients with OP encompasses clinical risk factors, bone mineral density measurements and FRAX risk estimates. Non-pharmacological measures including adequate calcium and vitamin D, regular exercise and falls prevention are recommended. Pharmacological measures depend on patients' fracture risk status. Very high-risk individuals are recommended for treatment with an anabolic agent, if available, followed by an anti-resorptive agent. Alternatively, parenteral anti-resorptive agents can be used. High-risk individuals should be treated with anti-resorptive agents. In low-risk individuals, menopausal hormone replacement or selective estrogen receptor modulators can be used, if indicated. Patients should be assessed regularly to monitor treatment response and treatment adjusted, as appropriate.

Conclusions: 

The pathways for the management of postmenopausal OP in Malaysia have been updated. Incorporation of fracture risk stratification can guide appropriate treatment.

1. Camacho, P. M., Petak, S. M., Binkley, N., Diab, D. L., Eldeiry, L. S., Farooki, A., Harris, S. T., Hurley, D. L., Kelly, J., Lewiecki, E. M., Pessah-Pollack, R., McClung, M., Wimalawansa, S. J., & Watts, N. B. (2020). American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocrine Practice, 26(Suppl 1), 1–46. https://doi.org/10.4158/GL-2020-0524SUPPL
2. Söreskog, E., Ström, O., Spångéus, A., Åkesson, K. E., Borgström, F., Banefelt, J., & Kanis, J. A. (2020). Risk of major osteoporotic fracture after first, second and third fracture in Swedish women aged 50 years and older. Bone, 134, Article 115247. https://doi.org/10.1016/j.bone.2020.115247
3. Cheung, C. L., Ang, S. B., Chadha, M., Chow, E. S., Chung, Y. S., Hew, F. L., Jaisamrarn, U., Ng, H., Oates, M., Shin, C. S., Teo, K., Tu, S. T., Xia, W. B., Yu, J., & Yoon, B. K. (2018). An updated hip fracture projection in Asia: The Asian Federation of Osteoporosis Societies study. Osteoporosis and Sarcopenia, 4(1), 16–21. https://doi.org/10.1016/j.afos.2018.03.003
4. Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014). National Osteoporosis Foundation clinician's guide to prevention and treatment of osteoporosis. Osteoporosis International, 25(10), 2359–2381. https://doi.org/10.1007/s00198-014-2794-2
5. Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J. Y. (2019). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International, 30(1), 3–44. https://doi.org/10.1007/s00198-018-4704-5
6. Shuhart, C. R., Yeap, S. S., Anderson, P. A., Jankowski, L. G., Lewiecki, E. M., Morse, L. R., Rosen, H. N., Schousboe, J. T., Shepherd, J. A., & Baim, S. (2019). Executive summary of the 2019 ISCD position development conference on monitoring treatment, DXA cross-calibration and least significant change, spinal cord injury, peri-prosthetic and orthopedic bone health, transgender medicine, and pediatrics. Journal of Clinical Densitometry, 22(4), 453–471. https://doi.org/10.1016/j.jocd.2019.07.001
7. National Institute for Health and Care Excellence. (2012). Osteoporosis – assessing the risk of fragility fractures (NICE Clinical Guideline CG146). https://www.nice.org.uk/guidance/cg146
8. Scottish Intercollegiate Guidelines Network. (2011). SIGN 50: A guideline developer's handbook. https://www.sign.ac.uk/assets/sign50_2011.pdf
9. Chandran, M., Mitchell, P. J., Amphansap, T., Bhadada, S. K., Chadha, M., Chan, D. C., Cheung, C. L., Chiowrishon, S., Choi, H. J., Choon, D., Francis, R. M., Hew, F. L., Khan, A., Mithal, A., Ong, T., Sripanyakorn, G., Tan, S. B., Thomas, N., Zhao, Y., ... & Yu, J. (2021). Development of the Asia Pacific Consortium on Osteoporosis (APCO) Framework: Clinical standards of care for the screening, diagnosis, and management of osteoporosis in the Asia-Pacific region. Osteoporosis International, 32(7), 1249–1275. https://doi.org/10.1007/s00198-020-05742-0
10. Koh, L. K., Sedrine, W. B., Torralba, T. P., Kung, A., Fujiwara, S., Chan, S. P., Huang, Q. R., Schmidt, R. U., Zhao, X. L., Lau, E. M., & OSTA Executive Committee. (2001). A simple tool to identify Asian women at increased risk of osteoporosis. Osteoporosis International, 12(8), 699–705. https://doi.org/10.1007/s001980170068
11. Shan, L. P., Bee, O. F., Suniza, S. S., & Adeeb, N. (2011). Developing a Malaysian Osteoporosis Screening Tool (MOST) for early osteoporosis detection in Malaysian women. Sexual & Reproductive Healthcare, 2(2), 77–82. https://doi.org/10.1016/j.srhc.2011.02.002
12. Kanis, J. A., Johnell, O., Oden, A., Johansson, H., & McCloskey, E. (2008). FRAX and the assessment of fracture probability in men and women from the UK. Osteoporosis International, 19(4), 385–397. https://doi.org/10.1007/s00198-007-0518-1
13. Weaver, C. M., Gordon, C. M., Janz, K. F., Kalkwarf, H. J., Lappe, J. M., Lewis, R., O'Karma, M., Wallace, T. C., & Zemel, B. S. (2016). The National Osteoporosis Foundation's position statement on peak bone mass development and lifestyle factors: A systematic review and implementation recommendations. Osteoporosis International, 27(4), 1281–1386. https://doi.org/10.1007/s00198-015-3440-3
14. Tai, V., Leung, W., Grey, A., Reid, I. R., & Bolland, M. J. (2015). Calcium intake and bone mineral density: Systematic review and meta-analysis. British Medical Journal, 351, Article h4183. https://doi.org/10.1136/bmj.h4183
15. Bischoff-Ferrari, H. A., Dawson-Hughes, B., Baron, J. A., Burckhardt, P., Li, R., Spiegelman D., Specker, B., Orav, J. E., Wong, J. B., Staehelin, H. B., O'Reilly, E., Kiel, D. P., & Willett, W. C. (2007). Calcium intake and hip fracture risk in men and women: A meta-analysis of prospective cohort studies and randomized controlled trials. American Journal of Clinical Nutrition, 86(6), 1780–1790. https://doi.org/10.1093/ajcn/86.6.1780
16. Tang, B. M., Eslick, G. D., Nowson, C., Smith, C., & Bensoussan, A. (2007). Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: A meta-analysis. The Lancet, 370(9588), 657–666. https://doi.org/10.1016/S0140-6736(07)61342-7
17. Bolland, M. J., Leung, W., Tai, V., Bastin, S., Gamble, G. D., Grey, A., & Reid, I. R. (2015). Calcium intake and risk of fracture: Systematic review. British Medical Journal, 351Trace, Article h4580. https://doi.org/10.1136/bmj.h4580
18. National Institutes of Health. (2020). Vitamin D: Fact sheet for health professionals. https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/
19. Thanapluetiwong, S., Chewcharat, A., Takkavatakarn, K., Praditpornsilpa, K., Eiam-Ong, S., & Susantitaphong, P. (2020). Vitamin D supplement on prevention of fall and fracture: A meta-analysis of randomized controlled trials. Medicine, 99(34), Article e21530. https://doi.org/10.1097/MD.0000000000021530
20. DIPART (Vitamin D Individual Patient Analysis of Randomized Trials) Group. (2010). Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. British Medical Journal, 340, Article b5463. https://doi.org/10.1136/bmj.b5463
21. Harvey, N. C., Biver, E., Kaufman, J. M., Bauer, J., Branco, J., Brandi, M. L., Bruyère, O., Canhão, H., Cherubini, A., Cooper, C., Diez-Perez, A., Egger, T., Laslop, A., Maggi, S., Minisola, S., Reginster, J. Y., Rizzoli, R., Szulc, P., Tanval, Tan., ... & ESCEO and IOF Committees. (2017). The role of calcium supplementation in healthy musculoskeletal ageing: An expert consensus meeting of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Foundation for Osteoporosis (IOF). Osteoporosis International, 28(2), 447–462. https://doi.org/10.1007/s00198-016-3773-6
22. de Kam, D., Smulders, E., Weerdesteyn, V., & Smits-Engelsman, B. C. (2009). Exercise interventions to reduce fall-related fractures and their risk factors in individuals with low bone density: A systematic review of randomized controlled trials. Osteoporosis International, 20(12), 2111–2125. https://doi.org/10.1007/s00198-009-0931-7
23. Iuliano-Burns, S., Saxon, L., Naughton, G., Gibbons, K., & Bass, S. L. (2003). Regional specificity of exercise and calcium during skeletal growth in girls: A randomized controlled trial. Journal of Bone and Mineral Research, 18(1), 156–162. https://doi.org/10.1359/jbmr.2003.18.1.156
24. Magkos, F., Kavouras, S. A., Yannakoulia, M., Karipidou, M., Sidossi, S., & Sidossis, L. S. (2007). The bone response to non-weight-bearing exercise is sport-, site-, and sex-specific. Clinical Journal of Sport Medicine, 17(2), 123–128. https://doi.org/10.1097/JSM.0b013e318038d8f8
25. Sherrington, C., Fairhall, N., Kwok, W., Wallbank, G., Tiedemann, A., Michaleff, Z. A., Ng, C. A. C., & Bauman, A. (2020). Evidence on physical activity and falls prevention for people aged 65+ years: Systematic review to inform the WHO guidelines on physical activity and sedentary behaviour. International Journal of Behavioral Nutrition and Physical Activity, 17, Article 144. https://doi.org/10.1186/s12966-020-01041-3
26. Zhao, R., Bu, W., & Chen, X. (2019). The efficacy and safety of exercise for prevention of fall-related injuries in older people with different health conditions, and differing intervention protocols: A meta-analysis of randomized controlled trials. BMC Geriatrics, 19, Article 341. https://doi.org/10.1186/s12877-019-1359-2
27. Guirguis-Blake, J., Michael, Y., Perdue, L., Coppola, E., Beil, T., & Thompson, J. (2018). Interventions to prevent falls in community-dwelling older adults: A systematic review for the U.S. Preventive Services Task Force (Evidence Synthesis No. 159). Agency for Healthcare Research and Quality.
28. Wong, R. M. Y., Chong, K. C., Law, S. W., Ho, W. T., Li, J., Chui, C. S., & Cheung, W. H. (2020). The effectiveness of exercises on fall and fracture prevention amongst community elderlies: A systematic review and meta-analysis. Journal of Orthopaedic Translation, 24, 58–65. https://doi.org/10.1016/j.jot.2020.04.003
29. Ng, C., Fairhall, N., Wallbank, G., Tiedemann, A., Michaleff, Z. A., & Sherrington, C. (2019). Exercise for falls prevention in community-dwelling older adults: Trial and participant characteristics, interventions and bias in clinical trials from a systematic review. BMJ Open Sport & Exercise Medicine, 5(1), Article e000663. https://doi.org/10.1136/bmjsem-2019-000663
30. Sherrington, C., Michaleff, Z. A., Fairhall, N., Paul, S. S., Tiedemann, A., Whitney, J., Cumming, R. G., Herbert, R. D., Close, J. C. T., & Lord, S. R. (2017). Exercise to prevent falls in older adults: An updated systematic review and meta-analysis. British Journal of Sports Medicine, 51(24), 1750–1758. https://doi.org/10.1136/bjsports-2016-096547
31. Sherrington, C., Fairhall, N. J., Wallbank, G. K., Tiedemann, A., Michaleff, Z. A., Howard, K., Clemson, L., Hopewell, S., & Lamb, S. E. (2019). Exercise for preventing falls in older people living in the community. Cochrane Database of Systematic Reviews, 2019(1), Article CD012424. https://doi.org/10.1002/14651858.CD012424.pub2
32. Wang, Q., Jiang, X., Shen, Y., Yao, P., Chen, J., Zhou, Y., & Chen, J. (2020). Effectiveness of exercise intervention on fall-related fractures in older adults: A systematic review and meta-analysis of randomized controlled trials. BMC Geriatrics, 20, Article 322. https://doi.org/10.1186/s12877-020-01720-x
33. National Institute for Health and Care Excellence. (2013). Falls in older people: Assessing risk and prevention (NICE Clinical Guideline CG161). https://www.nice.org.uk/guidance/cg161
34. Panel on Prevention of Falls in Older Persons, American Geriatrics Society and British Geriatrics Society. (2011). Summary of the updated American Geriatrics Society/British Geriatrics Society clinical practice guideline for prevention of falls in older persons. Journal of the American Geriatrics Society, 59(1), 148–157. https://doi.org/10.1111/j.1532-5415.2010.03234.x
35. Malaysian Society of Geriatric Medicine. (2020). Position statement on falls and fragility fractures.
36. Bruce, J., Ralhan, S., Sheridan, R., Westacott, K., Withers, E., Finnegan, S., Lall, R., Underhill, M., & PreFIT Study Team. (2017). The design and development of a complex multifactorial falls assessment intervention for falls prevention: The Prevention of Falls Injury Trial (PreFIT). BMC Geriatrics, 17, Article 116. https://doi.org/10.1186/s12877-017-0504-2
37. Gillespie, L. D., Robertson, M. C., Gillespie, W. J., Sherrington, C., Gates, S., Clemson, L. M., & Lamb, S. E. (2012). Interventions for preventing falls in older people living in the community. Cochrane Database of Systematic Reviews, 2012(9), Article CD007146. https://doi.org/10.1002/14651858.CD007146.pub3
38. Kanis, J. A., Harvey, N. C., McCloskey, E., Bruyère, O., Veronese, N., Lorentzon, M., Cooper, C., Rizzoli, R., & Reginster, J. Y. (2020). Algorithm for the management of patients at low, high and very high risk of osteoporotic fracture. Osteoporosis International, 31(1), 1–12. https://doi.org/10.1007/s00198-019-05190-2
39. Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., & Vogt, T. M. (1996). Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. The Lancet, 348(9041), 1535–1541. https://doi.org/10.1016/S0140-6736(96)07088-2
40. Cummings, S. R., Black, D. M., Thompson, D. E., Applegate, W. B., Barrett-Connor, E., Musliner, T. A., Palermo, L., Prineas, R., Rubin, S. M., Scott, J. C., Vogt, T., Wallace, R., Yates, A. J., & Santora, A. C. (1998). Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA, 280(24), 2077–2082. https://doi.org/10.1001/jama.280.24.2077
41. Papapoulos, S. E., Quandt, S. A., Liberman, U.A., Hochberg, M. C., & Thompson, D. E. (2005). Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporosis International, 16(5), 468–474. https://doi.org/10.1007/s00198-004-1721-6
42. Richy, F., Schacht, E., Bruyere, O., Ethgen, O., Gourlay, M., & Reginster, J. Y. (2005). Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: A comparative meta-analysis. Calcified Tissue International, 76(3), 176–186. https://doi.org/10.1007/s00223-004-0259-7
43. Avenell, A., Gillespie, W. J., Gillespie, L. D., & O'Connell, D. L. (2005). Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database of Systematic Reviews, 2005(3), Article CD000227. https://doi.org/10.1002/14651858.CD000227.pub2
44. Eleni, A., & Panagiotis, P. (2020). A systematic review and meta-analysis of vitamin D and calcium in preventing osteoporotic fractures. Clinical Rheumatology, 39(12), 3571–3579. https://doi.org/10.1007/s10067-020-05234-y
45. Cummings, S. R., San Martin, J., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Burger, P., Roux, C., Felsenberg, D., Hochberg, M. C., Benhamou, C. L., Bolognese, M. A., Seeman, E., Garcia-Hernandez, E., Kendler, D. L., Yamashita, T., Bone, H. G., Brandi, M. L., ... & FREEDOM Trial Committee. (2009). Denosumab for prevention of fractures in postmenopausal women with osteoporosis. New England Journal of Medicine, 361(8), 756–765. https://doi.org/10.1056/NEJMoa0809493
46. Stakkestad, J. A., Lakatos, P., Lorenc, R., Sedarati, F., Neate, C., & Reginster, J. Y. (2008). Monthly oral ibandronate is effective and well tolerated after 3 years: The MOBILE long-term extension. Clinical Rheumatology, 27(8), 955–960. https://doi.org/10.1007/s10067-008-0834-0
47. Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., Delmas, P. D., & Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). (2004). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. Journal of Bone and Mineral Research, 19(8), 1241–1249. https://doi.org/10.1359/JBMR.040311
48. Cauley, J. A., Robbins, J., Chen, Z., Cummings, S. R., Jackson, R. D., LaCroix, A. Z., LeBoff, M., Lewis, C. E., Manson, J. E., Nevitt, M. C., Stefanick, M. L., Wright, C., & Women's Health Initiative Investigators. (2003). Effects of estrogen plus progestin on risk of fracture and bone mineral density: The Women's Health Initiative randomized trial. JAMA, 290(13), 1729–1738. https://doi.org/10.1001/jama.290.13.1729
49. Delmas, P. D., Ensrud, K. E., Adachi, J. D., Harper, K. D., Sarkar, S., Gennari, C., Reginster, J. Y., Pols, H. A., Recker, R. R., Harris, S. T., Burger, H., Fuchs-Bayle, K., & Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. (2002). Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial. Journal of Clinical Endocrinology & Metabolism, 87(8), 3609–3617. https://doi.org/10.1210/jcem.87.8.8752
50. Reginster, J., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Avron, A., Charles, G., & Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. (2000). Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis International, 11(1), 83–91. https://doi.org/10.1007/s001980050010
51. McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., Meunier, P. J., Reginster, J. Y., & Hip Intervention Program Study Group. (2001). Effect of risedronate on the risk of hip fracture in elderly women. New England Journal of Medicine, 344(5), 333–340. https://doi.org/10.1056/NEJM200102013440503
52. Cosman, F., Crittenden, D. B., Adachi, J. D., Binkley, N., Czerwinski, E., Ferrari, S., ... & Grauer, A. (2016). Romosozumab treatment in postmenopausal women with osteoporosis. New England Journal of Medicine, 375(16), 1532–1543. https://doi.org/10.1056/NEJMoa1607941
53. Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J. Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., Wang, O., & Mitlak, B. H. (2001). Effect of parathyroid hormone on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal of Medicine, 344(19), 1434–1441. https://doi.org/10.1056/NEJM200105103441904
54. Barrionuevo, P., Kapoor, E., Asi, N., Alahdab, F., Mohammed, K., Benkhadra, K., Almasri, J., Farah, W., Prokop, L. J., Takwoingi, Y., Wang, Z., & Murad, M. H. (2019). Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: A network meta-analysis. Journal of Clinical Endocrinology & Metabolism, 104(5), 1623–1630. https://doi.org/10.1210/jc.2019-00192
55. Cummings, S. R., Ettinger, B., Delmas, P. D., Kenemans, P., Stathopoulos, V., Verweij, P., ... & LIFT Trial Investigators. (2008). The effects of tibolone in older postmenopausal women. New England Journal of Medicine, 359(7), 697–708. https://doi.org/10.1056/NEJMoa0800743
56. Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., ... & HORIZON Pivotal Fracture Trial Committee. (2007). Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. New England Journal of Medicine, 356(18), 1809–1822. https://doi.org/10.1056/NEJMoa067312
57. The 2017 Hormone Therapy Position Statement of the North American Menopause Society. (2017). Menopause, 24(7), 728–753. https://doi.org/10.1097/GME.0000000000000921
58. de Villiers, T. J., Hall, J. E., Pinkerton, J. V., Pérez, S. C., Rees, M., Yang, C., & Goldstein, S. R. (2016). Revised global consensus statement on menopausal hormone therapy. Climacteric, 19(4), 313–315. https://doi.org/10.1080/13697137.2016.1196047
59. Formoso, G., Perrone, E., Maltoni, S., Balduzzi, S., Wilkinson, J., Basevi, V., Marata, A. M., Magrini, N., & D'Amico, R. (2016). Short-term and long-term effects of tibolone in postmenopausal women. Cochrane Database of Systematic Reviews, 2016(10), Article CD008536. https://doi.org/10.1002/14651858.CD008536.pub3
60. Cauley, J. A., Norton, L., Lippman, M. E., Eckert, S., Krueger, K. A., Purdie, D. W., Farrerons, J., Karasik, A., Mellström, D., Ng, K. W., Gennari, C., Powles, T., Reis, A., Goldstein, S., Mitlak, B. H., & MORE Investigators. (2001). Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Research and Treatment, 65(2), 125–134. https://doi.org/10.1023/A:1006478317111
61. Dell, R. M., Adams, A. L., Greene, D. F., Funahashi, T. T., Silverman, S. L., Eisemon, E. O., ... & ASBMR Task Force. (2012). Incidence of atypical nontraumatic diaphyseal fractures of the femur. Journal of Clinical Densitometry, 27(12), 2544–2550. https://doi.org/10.1002/jbmr.1719
62. Black, D. M., Geiger, E. J., Eastell, R., Vittinghoff, E., Li, B.H., Ryan, D. S., ... & ASBMR Task Force on Atypical Femur Fractures. (2020). Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. New England Journal of Medicine, 383(8), 743–753. https://doi.org/10.1056/NEJMoa1916525
63. Tile, L., & Cheung, A. M. (2020). Atypical femur fractures: Current understanding and approach to management. Therapeutic Advances in Musculoskeletal Disease, 12, Article 1759720X20916983. https://doi.org/10.1177/1759720X20916983
64. Shane, E., Burr, D., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., Dempster, D. W., Ebeling, P. R., Einhorn, T. A., Genant, H. K., Geusens, P., Klaushofer, K., Lane, J. M., McKiernan, F., McKinney, R., Ng, A. H., ... & ASBMR Task Force. (2014). Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research, 29(1), 1–23. https://doi.org/10.1002/jbmr.1998
65. Black, D. M., Kelly, M. P., Genant, H. K., Palermo, L., Eastell, R., Bucci-Rechtweg, C., ... & ASBMR Task Force. (2010). Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. New England Journal of Medicine, 362(19), 1761–1771. https://doi.org/10.1056/NEJMoa1001086
66. Khan, A. A., Morrison, A., Hanley, D. A., Felsenberg, D., McCauley, L. K., O'Ryan, F., ... & International Task Force on Osteonecrosis of the Jaw. (2015). Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus. Journal of Bone and Mineral Research, 30(1), 3–23. https://doi.org/10.1002/jbmr.2405
67. Lo, J. C., O'Ryan, F. S., Gordon, N. P., Yang, J., Hui, R. L., Martin, D., ... & Kaiser Permanente ONJ Cohort Study Group. (2010). Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. Journal of Oral and Maxillofacial Surgery, 68(2), 243–253. https://doi.org/10.1016/j.joms.2009.09.062
68. Rizzoli, R., Burlet, N., Cahall, D., Delmas, P. D., Eriksen, E. F., Felsenberg, D., Grbic, J., Jerews, J., Kanis, J. A., Kaufman, J. M., Mesen, S., Papapoulos, S., Reese, M., & Syversen, U. (2008). Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone, 42(5), 841–847. https://doi.org/10.1016/j.bone.2008.01.003
69. Capsoni, F., Longhi, M., & Weinstein, R. (2006). Bisphosphonate-associated osteonecrosis of the jaw: The rheumatologist's role. Arthritis Research & Therapy, 8(6), Article 219. https://doi.org/10.1186/ar2085
70. Hellstein, J. W., Adler, R. A., Edwards, B., Jacobsen, P. L., Kalmar, J. R., Koka, S., ... & American Dental Association Council on Scientific Affairs. (2011). Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: Executive summary of recommendations from the American Dental Association Council on Scientific Affairs. Journal of the American Dental Association, 142(11), 1243–1251. https://doi.org/10.14219/jada.archive.2011.0108
71. Adler, R. A., El-Hajj Fuleihan, G., Bauer, D. C., Camacho, P. M., Clarke, B. L., Clines, G. A., Compston, J. E., Drake, M. T., Edwards, B. J., Favus, M. J., Greenspan, S. L., McKinney, R., Pignolo, R. J., Sellmeyer, D. E., Shamtha, S., ... & ASBMR Task Force. (2016). Managing osteoporosis in patients on long-term bisphosphonate treatment: Report of a task force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research, 31(1), 16–35. https://doi.org/10.1002/jbmr.2708
72. Curtis, J. R., Saag, K. G., Arora, T., Wright, N. C., Yun, H., Daigle, S., ... & Delzell, E. (2020). Duration of bisphosphonate drug holidays and associated fracture risk. Medical Care, 58(5), 419–426. https://doi.org/10.1097/MLR.0000000000001294
73. Baron, R., Ferrari, S., & Russell, R. G. (2011). Denosumab and bisphosphonates: Different mechanisms of action and effects. Bone, 48(4), 677–692. https://doi.org/10.1016/j.bone.2010.11.020
74. Tsourdi, E., Langdahl, B., Cohen-Solal, M., Aubry-Rozier, B., Eriksen, E. F., Guañabens, N., Obermayer-Pietsch, B., Ralston, S. H., Eastell, R., & Zillikens, M. C. (2017). Discontinuation of denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. Bone, 105, 11–17. https://doi.org/10.1016/j.bone.2017.08.003
75. Cummings, S. R., Ferrari, S., Eastell, R., Gilchrist, N., Jensen, J. B., McClung, M., ... & FREEDOM Trial Committee. (2018). Vertebral fractures after discontinuation of denosumab: A post hoc analysis of the randomized placebo-controlled FREEDOM Trial and its Extension. Journal of Bone and Mineral Research, 33(2), 190–198. https://doi.org/10.1002/jbmr.3337
76. McClung, M. R., Wagman, R. B., Miller, P. D., Wang, A., & Lewiecki, E. M. (2017). Observations following discontinuation of long-term denosumab therapy. Osteoporosis International, 28(5), 1723–1732. https://doi.org/10.1007/s00198-017-3919-1
77. Murad, M. H., Drake, M. T., Mullan, R. J., Mauck, K. F., Stuart, L. M., Lane, M. A., ... & Montori, V. M. (2012). Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: A systematic review and network meta-analysis. Journal of Clinical Endocrinology & Metabolism, 97(6), 1871–1880. https://doi.org/10.1210/jc.2011-3060
78. Keaveny, T. M., Hoffmann, P. F., Singh, M., Palermo, L., Bilezikian, J. P., Greenspan, S. L., ... & Black, D. M. (2008). Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. Journal of Bone and Mineral Research, 23(12), 1974–1982. https://doi.org/10.1359/jbmr.080805
79. Black, D. M., Bilezikian, J. P., Ensrud, K. E., Greenspan, S. L., Palermo, L., Hue, T., ... & PaTH Study Investigators. (2005). One year of alendronate after one year of parathyroid hormone for osteoporosis. New England Journal of Medicine, 353(6), 555–565. https://doi.org/10.1056/NEJMoa050336
80. Eastell, R., Nickelsen, T., Marin, F., Barker, C., Hadji, P., Farrerons, J., ... & EUROFORS Investigators. (2009). Sequential treatment of severe postmenopausal osteoporosis after teriparatide: Final results of the Randomized, Controlled European Study of Forsteo (EUROFORS). Journal of Bone and Mineral Research, 24(4), 726–736. https://doi.org/10.1359/jbmr.081211
81. Appelman-Dijkstra, N. M., & Oei, H. L. D. W. (2022). The effect of osteoporosis treatment on bone mass. Best Practice & Research Clinical Endocrinology & Metabolism, 36(2), Article 101651. https://doi.org/10.1016/j.beem.2022.101651
82. McClung, M. R., Brown, J. P., Diez-Perez, A., Resch H., Caminis, J., Meisner, P., ... & Grauer, A. (2018). Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: A randomized, double-blind, phase 2, parallel group study. Journal of Bone and Mineral Research, 33(8), 1397–1406. https://doi.org/10.1002/jbmr.3458
83. Saag, K. G., Petersen, J., Brandi, M. L., Karaplis, A. C., Lorentzon, M., Thomas, T., ... & ARCH Trial Committee. (2017). Romosozumab or alendronate for fracture prevention in women with osteoporosis. New England Journal of Medicine, 377(15), 1417–1427. https://doi.org/10.1056/NEJMoa1708322
84. Lewiecki, E. M., Blicharski, T., Goemaere, S., Lippuner, K., Meisner, P. D., Miller, P. D., ... & Libanati, C. (2018). A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. Journal of Clinical Endocrinology & Metabolism, 103(9), 3183–3193. https://doi.org/10.1210/jc.2017-02163
85. Amgen, Inc. (2018). BLA 761062 romosozumab: U.S. Food and Drug Administration/Center for Drug Evaluation and Research multidisciplinary review and evaluation document (Vol. 9). Amgen, Inc.
86. Diez-Perez, A., Adachi, J. D., Agnusdei, D., Bilezikian, J. P., Compston, J. E., Cummings, S. R., ... & IOF Committee of Scientific Advisors. (2012). Treatment failure in osteoporosis. Osteoporosis International, 23(12), 2769–2774. https://doi.org/10.1007/s00198-012-2093-y
87. Confavreux, C. B., Paccou, J., David, C., Mehsen, N., Leboime, A., & Thomas, T. (2010). Defining treatment failure in severe osteoporosis. Joint Bone Spine, 77(Suppl 2), S128–S132. https://doi.org/10.1016/S1297-319X(10)70010-3
88. Ross, S., Samuels, E., Gairy, K., Iqbal, S., Badamgarav, E., & Siris, E. (2011). A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value in Health, 14(4), 571–581. https://doi.org/10.1016/j.jval.2010.11.010
89. Hofbauer, L. C., Hamann, C., & Ebeling, P. R. (2010). Approach to the patient with secondary osteoporosis. European Journal of Endocrinology, 162(6), 1009–1020. https://doi.org/10.1530/EJE-10-0015
90. Carmel, A. S., Shieh, A., Bang, H., & Bockman, R. S. (2012). The 25(OH)D level needed to maintain a favourable bisphosphonate response is ≥33 ng/ml. Osteoporosis International, 23(10), 2479–2487. https://doi.org/10.1007/s00198-011-1857-4
91. Nakamura, Y., Suzuki, T., Kamimura, M., Murakami, K., Ikegami, S., Uchiyama, S., & Kato, H. (2017). Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment. Bone Research, 5, Article 17021. https://doi.org/10.1038/boneres.2017.21